Stay updated with breaking news from Media Outside. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023Lecanemab collaboration to continue unchanged globallyLecanemab
Cambridge, MA, Jan 28, 2022 - (JCN Newswire) - Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM
CAMBRIDGE, Mass., Jan. 27, 2022Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM (aducanumab-avwa)
>> man in stripes: enjoy, enjoy. >> anthony: people have been ridiculously nice to us. aren't you guys supposed to be the axis of evil? >> farrokh: you, you're absolutely right. we are demonized by the media outside. you show black and white, people are demonstrating and killing and bombing and this and that and you see it in this and that. but you never talk about the real people who are actually living peacefully inside the country, you know? because eventually, in the future of the world, we and americans have a very special place in this middle east. you cannot play a game without consider...
CAMBRIDGE, Mass., Dec. 22, 2021Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the First Committee on New Drugs (NDC) of the Pharmaceutical Affairs and Food Sanitation Council